Novartis Narrows Entresto Fight With MSN, Noratech Deals
Novartis Pharmaceuticals Corp. has come closer to fully keeping a generic version of its blockbuster drug Entresto off the market, with MSN Pharmaceuticals Inc. backing down on its most contentious appeal...To view the full article, register now.
Already a subscriber? Click here to view full article